Dr. Marty Makary will answer questions from a Senate panel about his plans to lead the Food and Drug Administration.

Johnson & Johnson will stop late-stage studies of its experimental drug to treat major depressive disorder due to a lack of ...

Johnson & Johnson said on Thursday it will discontinue a late-stage study of its add-on treatment for major depressive ...

Completion of the first implantation procedure marks the start of Abbott’s pivotal deep brain stimulation trial in ...

Explore how ketamine, a powerful dissociative drug, may be impacting Elon Musk's behavior and decision-making, raising ...

Muslima Abdi, a well-wisher who took him to the hospital, described Nura’s difficult background, highlighting the lack of support he faced in overcoming drug addiction, which ultimately led to his ...

A new federal commission will ‘investigate’ decades-old mental health as well as weight loss drugs, prompting concerns from ...

For nearly five years, people with attention deficit/hyperactivity disorder have had the option of getting their stimulant medications prescribed and renewed by doctors they see only over a computer ...

The rapid influx of new medications brought to market over the past decade has revolutionized health care by offering new ...

The use of GLP-1 receptor agonists corresponded with a lower risk for depression among older adults with type 2 diabetes ...

The research constitutes some of the first evidence that the condition is associated with modifications in the brain before ...